At least we have lost the crowd that was convinced we would be in the twenties. That simply can't be as no matter how good Brigatinib is, there are/will be three other ALK+ compounds that will most certainly gain some market share, especially since the other companies have large sales force. At least that is what I've seen tweeted.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.